Eli Lilly and Company LLY reported second-quarter 2023 adjusted earnings per share of $2.11, which beat the Zacks Consensus Estimate of $1.98.

Eli Lilly not only beat earnings per share (EPS) expectations with a non-GAAP EPS of $2.58 compared to the analysts' consensus figure of $2.47, but also showcased an impressive revenue increase.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Summary. Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

TD Cowen analyst Steve Scala has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Steve Scala has given his Buy rat ...

Eli Lilly and Company (NYSE:LLY) Number of Hedge Fund Holders In Q2 2024: 100. Projected EPS Growth Rate: 50.6%. Eli Lilly and Company (NYSE:LLY) is a mega pharmaceutical company that sells ...

Eli Lilly and Company (NYSE:LLY) last week reported its latest yearly results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations.

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...